United Kingdom
Ireland United KingdomFranceDeutschlandItalianSpanishChina

New Agreement for Diclectin in Key European Countries

ALLIANCE PHARMA PLC
("Alliance" or the "Group")

New Agreement for Diclectin in Key European Countries

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce that it has signed a further licensing and distribution agreement with Duchesnay Inc. of Canada for Diclectin, a proven product to treat nausea and vomiting of pregnancy. Alliance acquired UK rights to Diclectin in January 2015 and this additional agreement secures rights to launch the product in a further nine EU countries including Germany, France and Italy (the "Selected Territories"). 

This is Alliance's first significant distribution agreement since acquiring the Sinclair Healthcare Products business in December 2015, which substantially increased Alliance's European footprint.

Diclectin has a well-established efficacy and safety profile and is regarded as the standard of care for nausea and vomiting of pregnancy in Canada, where it has been used for over 30 years and has been prescribed for more than 30 million women. In 2013, it was approved in the United States with an FDA Category A safety rating for drugs used during pregnancy. Sales continue to grow strongly in the US, where it is marketed as Diclegis®.

In the Selected Territories there are approximately 2.5 million pregnancies each year, and approximately 70% of women will suffer nausea and vomiting with severe symptoms in 30% of them. It is estimated that 35% of pregnant women need time off work due to nausea and vomiting of pregnancy.  

Alliance has been progressing Diclectin through the marketing authorisation process in the UK and anticipates the product's launch in the second half of 2017. It is expected that regulatory approvals for the further European territories will follow around a year later. 

Commenting on the agreement, John Dawson, Alliance Pharma's Chief Executive, said:

"We are delighted to build on our existing partnership with Duchesnay by acquiring the licensing and distribution rights to Diclectin in a further nine EU countries. This new agreement highlights the potential of our strengthened European distribution base following the acquisition last year of the Sinclair Healthcare Products business." 

Eric Gervais, Duchesnay's Executive Vice-President, added:

"Since we signed the UK rights for Diclectin, our two companies have collaborated closely and we are very pleased to have agreed further rights for Diclectin with Alliance.  I know both companies are looking forward to replicating our success in the US and we look forward to making this product available across Europe as soon as possible."

For further information: 

Alliance Pharma plc  + 44 (0) 1249 466966
John Dawson, Chief Executive
Andrew Franklin, Chief Financial Officer
Sarah Robinson, Company Secretary
www.alliancepharma.co.uk
 
Buchanan   + 44 (0) 20 7466 5000
Mark Court / Sophie Cowles / Jane Glover
 
Numis Securities Limited  + 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black / Toby Adcock
 
Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international specialty pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH